Perhexiline maleate-induced hepatitis.
N Satz, M Täuber, R Streuli, M A Spycher, R Maurer
Index: Hepatogastroenterology. 38(4) , 314-6, (1991)
Full Text: HTML
Abstract
We report on a case of perhexiline maleate-induced hepatitis secondary to a long-term administration of recommended daily dosages of 300 mg. The patient had a spectacular weight loss of 29 kg. He developed hepatitis, which subsided after drug withdrawal. Our electron-microscopic findings with the typical inclusion bodies and impaired hydroxylation capacity point to an underlying metabolic disorder as the pathogenetic mechanism.
Related Compounds
Related Articles:
Torsade de pointes associated with perhexiline maleate therapy.
1990-12-01
[Aust. N. Z. J. Med. 20(6) , 818-20, (1990)]
Further studies on the pharmacokinetics of perhexiline maleate in humans.
1986-01-01
[Xenobiotica 16(1) , 63-8, (1986)]
1995-02-01
[Res. Commun. Mol. Pathol. Pharmacol. 87(2) , 115-23, (1995)]
A case series of concomitant treatment of perhexiline with amiodarone.
2012-04-01
[Ther. Drug Monit. 34(2) , 227-31, (2012)]
1988-09-15
[Biochem. Pharmacol. 37(18) , 3461-5, (1988)]